• . A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. ASCO Annual Meeting 2016. J Clin Oncol 33, 2015 (suppl; abstr TPS5072)


  • . N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol 2014

  • . Characterization of niphatenones that inhibit androgen receptor N-terminal domain. PLoS One 2014


  • . An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 2013

  • . Spongian diterpenoids inhibit androgen receptor activity. Mol Cancer Ther 2013